Importance of Identifying Cognitive Impairment in Multiple Sclerosis.
Sarah A MorrowChantal BaldwinSamir AlkabiePublished in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2022)
This article aims to highlight the impact of cognitive impairment on outcomes and quality of life for people with multiple sclerosis (MS) and to review current evidence for the efficacy of disease-modifying therapies (DMTs) and other interventions. In addition, we provide clinical practice insights regarding screening and management of cognitive impairment in people with MS. Evidence suggests that cognitive deterioration often accompanies magnetic resonance imaging changes. Neocortical volume and deep grey matter atrophy correlate with cognitive impairment. Similarly, cognitive decline is predictive of a higher lesion burden. Cognitive impairment is an important clinical measure of disability and negatively impacts quality of life. Phase 3 studies suggest that DMTs such as natalizumab, ozanimod and fingolimod may provide long-lasting, clinically meaningful effects on cognition in people with MS. Further data are needed to support the use of adjunct cognitive behavioural and exercise interventions for people with MS who have cognitive impairment. More data are needed to define appropriate management strategies for cognitive impairment in people with MS. Baseline and periodic screening for cognitive impairment and inclusion of cognitive impairment as a clinical trial endpoint will help to inform efforts to manage this important aspect of MS.
Keyphrases
- cognitive impairment
- multiple sclerosis
- white matter
- mass spectrometry
- magnetic resonance imaging
- cognitive decline
- clinical trial
- ms ms
- physical activity
- clinical practice
- type diabetes
- randomized controlled trial
- computed tomography
- metabolic syndrome
- study protocol
- risk factors
- skeletal muscle
- quality improvement
- data analysis